We aim to provide rapid and high quality access to the right medicines for the right patients with the hardest-to-treat cancers.

We are creating a pipeline of precision oncology treatments aimed at patients with unaddressed mutations across well-established oncology targets.

Foresight Platform

In order for us to address the unmet needs of our diverse patient population with mutations of unknown significance, we have developed Foresight, a groundbreaking, AI-driven, functional genomics platform that allows us to “match” patients with unaddressed mutations to clinic-ready therapies on a “1-to-1” basis. 

Following strong preclinical results, we’re currently running clinical trials

Following strong preclinical results, an active phase 1/2 study is currently underway to assess the safety and pharmacokinetics of our lead candidate Plixorafenib in patients with advanced, unresectable solid tumors.

The safety and efficacy of the following investigational compounds have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

Join a growing leader in the biotech industry.